Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Cash from Operations data on record, last reported at 54249000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 37.59% year-over-year to 54249000.0; the TTM value through Dec 2025 reached 204883000.0, down 52.13%, while the annual FY2025 figure was 204883000.0, 52.13% down from the prior year.
  • Cash from Operations reached 54249000.0 in Q4 2025 per OCUL's latest filing, down from 50725000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 7732000.0 in Q3 2023 and bottomed at 55238000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 26747350.0, with a median of 20065500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: soared 45.77% in 2022, then tumbled 372.83% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 15153000.0 in 2021, then fell by 11.91% to 16958000.0 in 2022, then plummeted by 32.41% to 22454000.0 in 2023, then tumbled by 75.6% to 39429000.0 in 2024, then tumbled by 37.59% to 54249000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 54249000.0 in Q4 2025, 50725000.0 in Q3 2025, and 55238000.0 in Q2 2025.